Voltron Therapeutics, Inc. — Form D
Voltron Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2022-06-16. The offering totals $5.0M, of which $300K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-06-16
- Form: D
- Accession: 0001493152-22-016994
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $5.0M
- Amount sold: $300K
- Remaining: $4.7M
- Investors: 1
- Date of first sale: 2022-06-03
- Security types: equity, debt
- Revenue range: Decline to Disclose
- SEC file number: 021-449491
Issuer
- Name: Voltron Therapeutics, Inc.
- CIK: 0001835742
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 12 E 49TH STREET, NEW YORK, NY, 10017
- Phone: 646-335-5923
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| James Ahern | Director | New York, NY |
| Matthew Eitner | Director | New York, NY |
| Patrick Gallagher | Director | Charlotte, NC |
| Patrick Gallagher | Executive Officer | Charlotte, NC |
| Matthew Duffy | Director | New York, NY |
| Matthew Duffy | Executive Officer | New York, NY |
| Anthony Zook | Director | Charlotte, NC |
| Paul Korner | Director | New York, NY |
Other filings by this issuer (4)
More